Alkermes (8AK) Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
8AK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Alkermes plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.60 |
| 52 Week High | US$32.00 |
| 52 Week Low | US$22.00 |
| Beta | 0.49 |
| 1 Month Change | -18.62% |
| 3 Month Change | -1.67% |
| 1 Year Change | -24.36% |
| 3 Year Change | -4.30% |
| 5 Year Change | n/a |
| Change since IPO | 120.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8AK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.1% | 7.7% | 0.2% |
| 1Y | -24.4% | 3.8% | 2.1% |
Return vs Industry: 8AK underperformed the German Biotechs industry which returned 3.8% over the past year.
Return vs Market: 8AK underperformed the German Market which returned 2.1% over the past year.
Price Volatility
| 8AK volatility | |
|---|---|
| 8AK Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in DE Market | 14.4% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 8AK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8AK's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 2,050 | Richard Pops | www.alkermes.com |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
Alkermes plc Fundamentals Summary
| 8AK fundamental statistics | |
|---|---|
| Market cap | €3.99b |
| Earnings (TTM) | €208.77m |
| Revenue (TTM) | €1.28b |
Is 8AK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8AK income statement (TTM) | |
|---|---|
| Revenue | US$1.48b |
| Cost of Revenue | US$196.46m |
| Gross Profit | US$1.28b |
| Other Expenses | US$1.04b |
| Earnings | US$241.66m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.45 |
| Gross Margin | 86.69% |
| Net Profit Margin | 16.37% |
| Debt/Equity Ratio | 0% |
How did 8AK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 23:40 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkermes plc is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Baird |
| Joel Beatty | Baird |
| Luke Herrmann | Baird |